SEARCH

SEARCH BY CITATION

REFERENCES

  • Alzheimer A. 1906. Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde. Neurologisches Centralblatt 23: 11291136.
  • Alzheimer A. 1907. Über eine eigenartige Erkrankung der Hirnrinde. Centralblatt für Nervenheilkunde und Psychiatrie 30: 177179.
  • Andrade C. 1952. A peculiar form of peripheral neuropathy: familial atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75: 408427.
  • Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VMY, Trojanowski JQ, Iwatsubo T. 1998. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152: 879884.
  • Baskakov IV, Aagaard C, Mehlhorn I, Wille H, Groth D, Baldwin MA, Prusiner SB, Cohen FE. 2000. Self-assembly of recombinant prion protein of 106 residues. Biochemistry 39: 27922804.
  • Baskakov IV, Legname G, Baldwin MA, Prusiner SB, Cohen FE. 2002. β-rich oligomers are not on the pathway to amyloid formation by the prion protein in vitro. J Biol Chem (in press).
  • Biospace.com. 2002. Elan Corporation PLC (ELN) and Wyeth-Ayerst Laboratories provide update on status of Alzheimer's collaboration; suspended AN-1792. http://www.biospace.com/news_story.cfm?StoryID=8062715&full=1.
  • Blacker D, Tanzi RE. 1998. The genetics of Alzheimer's disease—current status and future prospects. Arch Neurol 55: 294296.
  • Blackley HKL, Sanders GHW, Davies MC, Roberts CJ, Tendler SJB, Wilkinson MJ. 2000. In situ atomic force microscopy study of β-amyloid fibrillization. J Mol Biol 298: 833840.
  • Blake CC. 1978. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å. J Mol Biol 121: 339356.
  • Brown RH. 1995. Amyotrophic lateral sclerosis—recent insights from genetics and transgenic mice. Cell 80: 687692.
  • Brownell B, Oppenheimer DR, Hughes JT. 1970. The central nervous system in motor neurone disease. J Neurol Neurosurg Psychiatry 33: 338357.
  • Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, Reaume AG, Scott RW, Cleveland DW. 1998. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281: 18511854.
  • Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo JS, Taddei N, Ramponi G, Dobson CM, Stefani M. 2002. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416: 507511.
  • Chen QS, Kagan BL, Hirakura Y, Xie CW. 2000. Impairment of hippocampal long-term potentiation by Alzheimer's amyloid β-peptides. J Neurosci Res 60: 6572.
  • Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim YS, Huang XD, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI. 2001. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30: 665676.
  • Chui DH, Tanahashi H, Ozawa K, Ikeda S, Checler F, Ueda O, Suzuki H, Araki W, Inoue H, Shirotani K, Takahashi K, Gallyas F, Tabira T. 1999. Transgenic mice with Alzheimer's presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med 5: 560564.
  • Cleveland DW. 1999. From Charcot to SOD1: mechanisms of selective motor neuron death in ALS. Neuron 24: 515520.
  • Cohen AS, Calkins E. 1959. Electron microscopic observation on a fibrous component in amyloid of diverse origins. Nature 183: 12021203.
  • Cohen FE, Prusiner SB. 1998. Pathologic conformations of prion proteins. Annu Rev Biochem 67: 793819.
  • Coimbra A, Andrade C. 1971a. Familial amyloid polyneuropathy: an electron microscope study of the peripheral nerve in five cases. I. Interstitial changes. Brain 94: 199206.
  • Coimbra A, Andrade C. 1971b. Familial amyloid polyneuropathy: an electron microscope study of the peripheral nerve in five cases. II. Nerve fibre changes. Brain 94: 207212.
  • Conway KA, Harper JD, Lansbury PT. 1998. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson's disease. Nat Med 4: 13181320.
  • Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT. 2000. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97: 571576.
  • Costa PP, Figueira AS, Bravo FR. 1978. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci USA 75: 44994503.
  • Cummings BJ, Pike CJ, Shankle R, Cotman CW. 1996. β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging 17: 921933.
  • Damas AM, Saraiva MJ. 2000. Review: TTR amyloidosis—structural features leading to protein aggregation and their implications on therapeutic strategies. J Struct Biol 130: 290299.
  • DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. 2001. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98: 88508855.
  • Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY, Getzoff ED, Hu P, Herzfeldt B, Roos RP. 1993. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 261: 10471051.
  • Dodart J-C, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. 2002. Immunizations reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat Neurosci 5: 452457.
  • Dodart JC, Meziane H, Mathis C, Bales KR, Paul SM, Ungerer A. 1999. Behavioral disturbances in transgenic mice overexpressing the V717F β-amyloid precursor protein. Behav Neurosci 113: 982990.
  • Donne DG, Viles JH, Groth D, Mehlhorn I, James TL, Cohen FE, Prusiner SB, Wright PE, Dyson HJ. 1997. Structure of the recombinant full-length hamster prion protein PrP(29-231): the N terminus is highly flexible. Proc Natl Acad Sci USA 94: 1345213457.
  • Doroudchi MM, Minotti S, Figlewicz DA, Durham HD. 2001. Nitrotyrosination contributes minimally to toxicity of mutant SOD1 associated with ALS. Neuroreport 12: 12391243.
  • Duff K, Rao MV. 2001. Progress in the modeling of neurodegenerative diseases in transgenic mice. Curr Opin Neurol 14: 441447.
  • El-Agnaf OM. 2000. Conformation and toxicity of the ABri peptide in familial British dementia [Abstract 497]. Neurobiol Aging 21: S110.
  • El-Agnaf OMA, Nagala S, Patel BP, Austen BM. 2001a. Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils. J Mol Biol 310: 157168.
  • El-Agnaf OMA, Sheridan JM, Sidera C, Siligardi G, Hussain R, Haris PI, Austen BM. 2001b. Effect of the disulfide bridge and the C-terminal extension on the oligomerization of the amyloid peptide ABri implicated in familial British dementia. Biochemistry 40: 34493457.
  • Esiri MM. 2001. The neuropathology of Alzheimer's disease. In: DawbarnD, AllenSJ, editors. Neurobiology of Alzheimer's disease. Oxford: Oxford University Press Oxford. p 3353.
  • Estevez AG, Crow JP, Sampson JB, Reiter C, Zhuang Y, Richardson GJ, Tarpey MM, Barbeito L, Beckman JS. 1999. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 286: 24982500.
  • Facchinetti F, Sasaki M, Cutting FB, Zhai P, MacDonald JE, Reif D, Beal MF, Huang PL, Dawson TM, Gurney ME, Dawson VL. 1999. Lack of involvement of neuronal nitric oxide synthase in the pathogenesis of a transgenic mouse model of familial amyotrophic lateral sclerosis. Neuroscience 90: 14831492.
  • Fischer M, Rulicke T, Raeber A, Sailer A, Moser M, Oesch B, Brandner S, Aguzzi A, Weissmann C. 1996. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J 15: 12551264.
  • Forloni G, Bugiani O, Tagliavini F, Salmona M. 1996. Apoptosis-mediated neurotoxicity induced by β-amyloid and PrP fragments. Mol Chem Neuropathol 28: 163171.
  • Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. 1995. Alzheimer's-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373: 523527.
  • Ghiso JA, Holton J, Miravalle L, Calero M, Lashley T, Vidal R, Houlden H, Wood N, Neubert TA, Rostagno A, Plant G, Revesz T, Frangione B. 2001. Systemic amyloid deposits in familial British dementia. J Biol Chem 276: 4390943914.
  • Gong YS, Chang L, Lambert MP, Viola KL, Krafft GA, Finch CE, Klein WL. 2001. Nonfibrillar Aβ toxins in AD: presence of ADDLs and ADDL-binding proteins in Alzheimer's disease brains. Soc Neurosci Abstr 27: 322.10.
  • Gotz J, Chen F, van Dorpe J, Nitsch RM. 2001. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils. Science 293: 14911495.
  • Griffiths RA, Mortimer TF, Oppenheimer DR, Spalding JM. 1982. Congophilic angiopathy of the brain: a clinical and pathological report on two siblings. J Neurol Neurosurg Psychiatry 45: 396408.
  • Haass C, Steiner H. 2001. Protofibrils, the unifying toxic molecule of neurodegenerative disorders? Nat Neurosci 4: 859860.
  • Hamilton JA. 2001. Transthyretin: a review from a structural perspective. Cell Mol Life Sci 58: 1491521.
  • Hamilton JA, Steinrauf LK, Braden BC, Liepnieks J, Benson MD, Holmgren G, Sandgren O, Steen L. 1993. The X-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30[RIGHTWARDS ARROW]Met variant to 1.7 Å resolution. J Biol Chem 268: 24162424.
  • Hardy J. 1997. The Alzheimer family of diseases—many etiologies, one pathogenesis. Proc Natl Acad Sci USA 94: 20952097.
  • Hardy JA, Higgins GA. 1992. Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184185.
  • Harper JD, Wong SS, Lieber CM, Lansbury PT. 1997. Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Chem Biol 4: 119125.
  • Harper JD, Wong SS, Lieber CM, Lansbury PT. 1999. Assembly of Aβ amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry 38: 89728980.
  • Hartley DM, Walsh DM, Ye CPP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ. 1999. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19: 88768884.
  • Hayward LJ, Rodriguez JA, Kim JW, Tiwari A, Goto JJ, Cabelli DE, Valentine JS, Brown RH. 2002. Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial ALS. J Biol Chem 277: 1592315931.
  • Howlett DR, Jennings KH, Lee DC, Clark MS, Brown F, Wetzel R, Wood SJ, Camilleri P, Roberts GW. 1995. Aggregation state and neurotoxic properties of Alzheimer's β-amyloid peptide. Neurodegeneration 4: 2332.
  • Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. 1999. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 96: 32283233.
  • Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang FS, Cole G. 1996. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274: 99102.
  • Hughes CP. 1982. A new clinical scale for the staging of dementia. Br J Psychiatry 140: 566572.
  • Ince PG, Lowe J, Shaw PJ. 1998. Amyotrophic lateral sclerosis—current issues in classification, pathogenesis, and molecular pathology. Neuropathol Appl Neurobiol 24: 104117.
  • James TL, Liu H, Ulyanov NB, Farr-Jones S, Zhang H, Donne DG, Kaneko K, Groth D, Mehlhorn I, Prusiner SB, Cohen FE. 1997. Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform. Proc Natl Acad Sci USA 94: 10086100891.
  • Johnston JA, Dalton MJ, Gurney ME, Kopito RR. 2000. Formation of high molecular weight complexes of mutant Cu,Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 97: 1257112576.
  • Khachaturian ZS. 1985. Diagnosis of Alzheimer's disease. Arch Neurol 42: 10971105.
  • Kidd M. 1964. Alzheimer's disease—an electron microscopical study. Brain 87: 307320.
  • Kim SH, Wang R, Gordon DJ, Bass J, Steiner DF, Lynn DG, Thinakaran G, Meredith SC, Sisodia SS. 1999. Furin mediates enhanced production of fibrillogenic ABri peptides in familial British dementia. Nat Neurosci 2: 984988.
  • Kirkitadze MD, Condron MM, Teplow DB. 2001. Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis. J Mol Biol 312: 11031119.
  • Klein WL, Krafft GA, Finch CE. 2001. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 24: 219224.
  • Koistinaho M, Ort M, Cimadevilla JM, Vondrous R, Cordell B, Koistinaho J, Bures J, Higgins LS. 2001. Specific spatial learning deficits become severe with age in β-amyloid precursor protein transgenic mice that harbor diffuse β-amyloid deposits but do not form plaques. Proc Natl Acad Sci USA 98: 1467514680.
  • Kopito RR. 2000. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10: 524530.
  • Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106108.
  • Kumar-Singh S, Dewachter I, Moechars D, Lubke U, De Jonghe C, Ceuterick C, Checler F, Naidu A, Cordell B, Cras P, Van Broeckhoven C, Van Leuven F. 2000. Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation. Neurobiol Dis 7: 922.
  • Kuroda Y, Kawahara M. 1994. Aggregation of amyloid β-protein and its neurotoxicity: Enhancement by aluminum and other metals. Tohoku J Exp Med 174: 263268.
  • Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. 1998. Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 64486453.
  • Larson J, Lynch G, Games D, Seubert P. 1999. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res 840: 2335.
  • Lashuel HA, Lai Z, Kelly JW. 1998. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. Biochemistry 37: 1785117864.
  • Lashuel HA, Wurth C, Woo L, Kelly JW. 1999. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry 38: 1356013573.
  • Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E. 2001. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 14871491.
  • Lewy FH. 1912. Paralysis agitans. Pathologische anatomie. In: LewandowskyM, editor, Handbüch der Neurologie, v. 2. Berlin: Springer-Verlag. p 920933.
  • Liu H, Farr-Jones S, Ulyanov NB, Llinas M, Marqusee S, Groth D, Cohen FE, Prusiner SB, James TL. 1999. Solution structure of Syrian hamster prion protein rPrP(90–231). Biochemistry 38: 53625377.
  • Liu Y, Schubert D. 1997. Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis. J Neurochem 69: 22852293.
  • Lu BY, Chang JY. 2001. Isolation of isoforms of mouse prion protein with PrPSC-like structural properties. Biochemistry 40: 1339013396.
  • Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. 1999. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155: 853862.
  • Mandelkow EM, Mandelkow E. 1998. Tau in Alzheimer's disease. Trends Cell Biol 8: 425427.
  • Manelli A, Dahlgren K, Krafft GA, LaDu MJ. 2001. Neurotoxicity induced by oligomeric versus fibrillar Aβ1–42. Soc Neurosci Abstr 27: 322.12.
  • Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L. 2002. β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 98: 1224512250.
  • Masliah E, Sisk A, Mallory M, Games D. 2001. Neurofibrillary pathology in transgenic mice overexpressing V717F β-amyloid precursor protein. J Neuropathol Exp Neurol 60: 357368.
  • Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. 1996. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer's disease. J Neurosci 16: 57955811.
  • McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. 1999. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46: 860866.
  • Mesulam NM. 1999. Neuroplasticity failure in Alzheimer's disease: Bridging the gap between plaques and tangles. Neuron 24: 521529.
  • Mirra SS. 1991. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 47986.
  • Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Van Den Haute C, Checler F, Godaux E, Cordell B, Van Leuven F. 1999. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274: 64836492.
  • Monaco HL. 2000. The transthyretin-retinol-binding protein complex. Biochim Biophys Acta-Prot Struct Mol Enzymol 1482: 6572.
  • Morris JC. 1993. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43: 24122414.
  • Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. 2000. High-level neuronal expression of Aβ(1–42) in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci 20: 40504058.
  • Mulder DW, Kurland LT, Offord KP, Beard CM. 1986. Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology 36: 511517.
  • Narhi L, Wood SJ, Steavenson S, Jiang YJ, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, Citron M. 1999. Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J Biol Chem 274: 98439846.
  • Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. 2000. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 283: 15711577.
  • Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Naslund J, Lannfelt L. 2001. The ‘Arctic’ APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nat Neurosci 4: 887893.
  • Nybo M, Svehag SE, Nielsen EH. 1999. An ultrastructural study of amyloid intermediates in Aβ1–42 fibrillogenesis. Scand J Immunol 49: 219223.
  • Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE, Rozovsky I, Stine WB, Snyder SW, Holzman TF, Krafft GA, Finch CE. 1995. Clusterin (ApoJ) alters the aggregation of amyloid β-peptide (Aβ1–42) and forms slowly sedimenting Aβ complexes that cause oxidative stress. Exp Neurol 136: 2231.
  • Pasinetti GM, Ho L, Pompl P. 2002. Amyloid immunization in Alzheimer's disease: do we promote amyloid scavenging at the cost of inflammatory degeneration? Neurobiol Aging (in press).
  • Percy ME, Andrews DF, Potter H. 2000. Peripheral marker of Alzheimer's disease. In: ScintoLFM, DaffnerKR, editors. Early diagnosis of Alzheimer's disease. Totowa, NJ: Humana Press. p 191268.
  • Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. 1993. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13: 16761687.
  • Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW. 1991. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 563: 311314.
  • Pitschke M, Prior R, Haupt M, Riesner D. 1998. Detection of single amyloid β-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med 4: 832834.
  • Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Diiorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276: 20452047.
  • Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, Butler AC. 1998. Molecular mapping of Alzheimer's-type dementia in Down's syndrome. Ann Neurol 43: 380383.
  • Prusiner SB. 1998. The prion diseases. Brain Pathol 8: 499513.
  • Prusiner SB. 2001. Shattuck lecture—Neurodegenerative diseases and prions. N Engl J Med 344: 15161526.
  • Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. 2002. Tau is essential to β-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 99: 63646369.
  • Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K. 1996. NMR structure of the mouse prion protein domain PrP(121–321). Nature 382: 180182.
  • Rodriguez JA, Valentine JS, Eggers DK, Roe JA, Tiwari A, Brown RH, Hayward LJ. 2002. Familial ALS-associated mutations decrease the thermal stability of distinctly metallated species of human copper/zinc superoxide dismutase. J Biol Chem 277: 1593215937.
  • Roher AE. 1991. β-Amyloid from Alzheimer's disease brains inhibits sprouting and survival of sympathetic neurons. Biochem Biophys Res Commun 174: 572579.
  • Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, Rahmani Z, Krizus A, McKenna-Yasek D, Cayabyab A, Gaston SM, Berger R, Tanzi RE, Halperin JJ, B H, Van den Bergh R, Hung WY, Bird T, Deng G, Mulder DW, Smyth C, Laing NG, Soriano E, Pericak-Vance M, Haines J, Rouleau GA, Gusella GS, Horvitz HR, Brown RHJ. 1993a. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 5962.
  • Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, Rahmani Z, Krizus A, McKenna-Yasek D, Cayabyab A, Gaston SM, Berger R, Tanzi RE, Halperin JJ, B H, Van den Bergh R, Hung WY, Bird T, Deng G, Mulder DW, Smyth C, Laing NG, Soriano E, Pericak-Vance M, Haines J, Rouleau GA, Gusella GS, Horvitz HR, Brown RHJ. 1993b. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. [Erratum]. Nature 364: 362.
  • Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, Martins R, Hockey A, Montgomery P, Beyreuther K, Masters CL. 1989. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med 320: 14461452.
  • Said G, Ropert A, Faux N. 1984. Length-dependent degeneration of fibers in Portuguese amyloid polyneuropathy: a clinicopathologic study. Neurology 34: 10251032.
  • Sankarapandi S, Zweier JL. 1999. Evidence against the generation of free hydroxyl radicals from the interaction of copper,zinc-superoxide dismutase and hydrogen peroxide. J Biol Chem 274: 3457634583.
  • Schenk DB, Seubert P, Lieberburg I, Wallace J. 2000. β-peptide immunization: a possible new treatment for Alzheimer's disease. Arch Neurol 57: 934936.
  • Selkoe DJ. 1991. The molecular pathology of Alzheimer's disease. Neuron 6: 487498.
  • Selkoe DJ. 1994. Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol 53: 438447.
  • Selkoe DJ. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741766.
  • Serpell LC. 2000. Alzheimer's amyloid fibrils: structure and assembly. Biochim Biophys Acta 1502: 1630.
  • Sharon R, Goldberg MS, Bar-Josef I, Betensky RA, Shen J, Selkoe DJ. 2001. α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci USA 98: 91109115.
  • Shearman MS, Hawtin SR, Tailor VJ. 1995. The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by β-amyloid peptides. J Neurochem 65: 218227.
  • Shearman MS, Ragan CI, Iversen LL. 1994. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of β-amyloid-mediated cell death. Proc Natl Acad Sci USA 91: 14701474.
  • Singh RJ, Karoui H, Gunther MR, Beckman JS, Mason RP, Kalyanaraman B. 1998. Reexamination of the mechanism of hydroxyl radical adducts formed from the reaction between familial amyotrophic lateral sclerosis-associated Cu,Zn superoxide dismutase mutants and H2O2. Proc Natl Acad Sci USA 95: 66756680.
  • Sousa MM, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ. 2001. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 159: 19932000.
  • Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. 1998. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95: 64696473.
  • Strömgren E. 1981. Heredopathia ophthalmo-oto-encephalica. In: VinkenPJ, BruynGW, editors. Handbook of clinical neurology. Amsterdam: Elsevier. p 150152.
  • Strömgren E, Dalby A, Dalby M, Ranheim B. 1970. Cataract, deafness, cerebral ataxia, psychosis and dementia: a new syndrome. Acta Neurol Scand 46: 9798.
  • Subramaniam JR, Lyons WE, Liu J, Bartnikas TB, Rothstein J, Price DL, Cleveland DW, Gitlin JD, Wong PC. 2002. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nat Neurosci 5: 301307.
  • Supattapone S, Bosque P, Muramoto T, Wille H, Aagaard C, Peretz D, Nguyen HOB, Heinrich C, Torchia M, Safar J, Cohen FE, DeArmond SJ, Prusiner SB, Scott M. 1999. Prion protein of 106 residues creates an artificial transmission barrier for prion replication in transgenic mice. Cell 96: 869878.
  • Teller JK, Russo C, Debusk LM, Angelini G, Zaccheo D, Dagnabricarelli F, Scartezzini P, Bertolini S, Mann DMA, Tabaton M, Gambetti P. 1996. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 2: 9395.
  • Teplow DB. 1998. Structural and kinetic features of amyloid β-protein fibrillogenesis. Int J Exp Clin Invest 5: 121142.
  • Terry RD. 2001. An honorable compromise regarding amyloid in Alzheimer's disease. Ann Neurol 49: 684.
  • Terry RD, Gonatas NK, Weiss M. 1964. Ultrastructural studies in Alzheimer's presenile dementia. Am J Pathol 44: 269297.
  • Tretiakoff MC. 1919. Contribution à l'etude de l'anatomie pathologique de locus niger de Soemmering. Thèse de Paris, No. 293, University of Paris.
  • Vidal R, Frangione B, Rostagno A, Mead S, Revesz T, Plant G, Ghiso J. 1999. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 399: 776781.
  • Vidal R, Revesz T, Rostagno A, Kim E, Holton JL, Bek T, Bojsen-Moller M, Braendgaard H, Plant G, Ghiso J, Frangione B. 2000. A decamer duplication in the 3′ region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci USA 97: 49204925.
  • Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT. 2001. Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40: 78127819.
  • Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Benedek GB, Selkoe DJ, Teplow DB. 1999. Amyloid β-protein fibrillogenesis: structure and biological activity of protofibrillar intermediates. J Biol Chem 274: 2594525952.
  • Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. 2002. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535539.
  • Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. 1997. Amyloid β-protein fibrillogenesis: detection of a protofibrillar intermediate. J Biol Chem 272: 2236422372.
  • Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL. 2002. Soluble oligomers of β amyloid(1–42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924: 133140.
  • Wang J, Dickson DW, Trojanowski JQ, Lee VMY. 1999. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158: 328337.
  • Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, O'Hare E, Esler WP, Maggio JE, Mantyh PW. 1998. Fibrillar β-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 18: 21612173.
  • Westermark P, Sletten K, Johansson B, Cornwell GG 3rd. 1990. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 87: 28432845.
  • Wiedau-Pazos M, Goto JJ, Rabizadeh S, Gralla EB, Roe JA, Lee MK, Valentine JS, Bredesen DE. 1996. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 271: 515518.
  • Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL. 1999. α-Synuclein fibrillogenesis is nucleation-dependent: implications for the pathogenesis of Parkinson's disease. J Biol Chem 274: 1950919512.
  • Worster-Drought C, Hill T, McMenemey W. 1933. Familial presenile dementia with spastic paralysis. J Neurol Psychopathol 14: 2734.
  • Yim HS, Kang JH, Chock PB, Stadtman ER, Yim MB. 1997. A familial amyotrophic lateral sclerosis-associated A4V Cu,Zn-superoxide dismutase mutant has a lower Km for hydrogen peroxide. Correlation between clinical severity and the Km value. J Biol Chem 272: 88618863.
  • Yim MB, Kang JH, Yim HS, Kwak HS, Chock PB, Stadtman ER. 1996. A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: an enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proc Natl Acad Sci USA 93: 57095714.
  • Zahn R, Liu A, Luhrs T, Riek R, von Schroetter C, Lopez Garcia F, Billeter M, Calzolai L, Wider G, Wuthrich K. 2000. NMR solution structure of the human prion protein. Proc Natl Acad Sci USA 97: 145150.